Portable, high-intensity neonatal LED phototherapy*

Country of origin | United States of America Treatment/resuscitation/palliative Primary use care/surgery Medical device (including in vitro

diagnostics)

Category

Commercial information _____

List price (USD): 2500

Year of commercialization: 2020

Number of units distributed: 250



Currently marketed in: Indonesia, Kuwait, Mongolia, Malaysia, United Arab Emirates and United States of America

Model: bili-hut global™

Product description ____

Ultraportable, high intensity LED phototherapy for the treatment of neonatal hyperbilirubinemia (jaundice)

Product details ____

Accessories: phototherapy swaddling garment (optional); bassinet cart adapter ("perch") Consumables: both reusable or disposable positioning "nest" options for infant are available Warranty duration: 3 years

Lifetime: 5 years

Energy requirements: 90-264 VAC 50/60 Hz

Facility requirements: Approved for hospital use. It may be set up at mother's side on a table, cart, trolley or crib.

Contact: Donna Brezinski, MD | Phone: +1 78 172 52460 | Web: https://rb.gy/g10r9c

* Information reported by manufacturer, October 2023

WHO assessment**

Clinical

Clinical Recommended Neonatal hyperbilirubinemia is a common occurrence in neonates, as the immature liver is unable to adequately metabolize bilirubin. High serum levels of bilirubin lead to its deposition in the skin, mucosae, and sclerae, thus manifesting as jaundice. Bilirubin may

also be deposited in the central nervous system, predominantly in the basal ganglia. If left untreated, this may lead to severe neurological impairment and death.

The standard of care for this condition is phototherapy which breaks down circulating bilirubin into molecules that can be excreted without hepatic metabolization. As the newborn's liver matures, it can adequately metabolize and excrete bilirubin and the phototherapy can be discontinued.

Despite being standard of care, the effective application of phototherapy in low-resource settings has been hindered by the medical devices used. Issues with size, transportability, robustness, and energy consumption have led to limited access to treatment across the globe. This technology attempts to overcome these limitations, greatly increasing treatment coverage while maintaining the standard for the adequate care of this condition.

— 40

2024

Comparison with WHO technical specifications

Cannot be verified.

The user manual provided is well detailed and it reports accurately the technical details. A technical brochure would give a better view of technical details but it is not strictly necessary in this case since the provided technical documents are complete. UNICEF has technical specifications available for a "Mobile LED phototherapy unit AC powered", but this is not a cot-shaped device but a mobile lamp. At the time of report creation, WHO phototherapy / hyperbilirubinemia / jaundice lamps or unit technical specifications were not available to compare the specific requirements of this type of technology.

Regulatory



Pre-market: This product is a Class IIa medical device and has obtained market approval in UAE, Indonesia, Kuwait, Mongolia, Malaysia, and the USA. Based on the certification and standards for the performance of this device, the documentation submitted is adequate to demonstrate the product is safe and effective.

Post-market: The manufacturer submitted partial post-market surveillance and vigilance documentation. According to the submission, there have been no recalls or adverse events since the release of Bili Hut. Nevertheless, it is considered good regulatory practice to establish the PM system before introducing the product to the market.

Quality management system (QMS): The manufacturer has submitted a valid ISO13485:2016 which is valid until 15 July 2025. Based on the certification and standards for performance, the product is safe and effective.

Security: The manufacturer did not submit the risk management documentation, which is crucial to ensure safety and performance of the device.

Health technology assessment



The device stands out due to its innovative design, featuring a curved, flexible canopy equipped with LED lights. This design provides multidirectional illumination, covering approximately 50% more skin area than standard of care (SoC) devices. It boasts a simple, collapsible structure, weighing under 4 kg and having a compact size, making it easy to store and transport in a carrying case. This portability allows it to be conveniently set up next to the mother in a hospital. Its semi-enclosed design helps to minimize heat loss, often removing the need for an incubator during treatment for most infants, and prevents light leakage into the surrounding area.

The device is safe, not posing any additional risks compared to SoC devices, and adheres to all relevant safety standards. The innovator manages risks in line with ISO 14971:2019 and upholds quality management according to ISO 13485. This technology has been utilized in various clinical settings worldwide for over three years without any reported adverse events.

It has proven to be highly reliable and effective, even under challenging conditions, with treatment times typically less than two days for nearly all patients, surpassing other SoC devices. This makes it particularly advantageous for low-resource areas where jaundice is more prevalent.

Technology 9 readiness level

- 41 —


Technology evidence Recommended assessment

WHO compendium of innovative health technologies for low-resource settings 2024

Health technology management







A notable concern is the device's recommended room temperature range of 70°F to 76°F (21.1°-24.4°C), which is quite narrow and more suited to controlled home settings. This temperature requirement is challenging to maintain in many areas where neonatal jaundice demands are the highest due to varying climate and infrastructural constraints. While the bili-hut is innovative and effective in treating jaundice and significant effort has been dedicated to testing usability and durability, its practicality in LRS hospital and home contexts is limited.

Intellectual property and local production



Intellectual property: It is patent-protected. To use this technology, authorization from the patent owner or the assignee is required.

Local production: Product design is advantageous for moderate to highvolume manufacturing. Moderate cost reduction can be achieved through local manufacturing. Local production is promising only for regions or markets with consistent, high annual product demand.

WHO guidance

 WHO recommendations on newborn health: guidelines approved by the WHO Guidelines Review Committee. (2017).
https://iris.who.int/bitstream/bandle/10665/259269/WHO-MCA-1707-eng.pdf2sequence=1

https://iris.who.int/bitstream/handle/10665/259269/WHO-MCA-17.07-eng.pdf?sequence=1